Review Article

Paroxysmal Sympathetic Hyperactivity in Moderate-to-Severe Traumatic Brain Injury and the Role of Beta-Blockers: A Scoping Review

Table 1

Summary of findings.

ArticlesStudy designParticipants mean or median ageTBI severityType of beta-blockers usedDosage of beta-blockersBeta-blockers were usedNon-beta-blockers drugsLength of stayMortality rate

Choi et al. [8]Narrative review26Moderate, severePropranololN/AIn combinationMorphine, baclofen, gabapentin, benzodiazepines, bromocriptineN/AN/A

Diamond et al. [21]Case report35.5SevereLabetalol10 mgIn combinationMorphineN/AN/A

Feng et al. [22]Narrative review18.1SeverePropranolol40 mg q12 h IVIn combinationMorphine, baclofen, gabapentin, benzodiazepine, bromocriptine, clonidine, dexmedetomidine, dantroleneN/AN/A

Godoy et al. [23]Letter to the editor28Moderate, severePropranolol20 mg q12 h to 20 mg q8 h IVIn combinationMorphine, fentanylN/AN/A

Schroeppel et al. 2014 [24]Case-control42SeverePropranolol85 mg IVAloneN/A443

Van der jagt and miranda. [25]Review55Moderate, severeAtenolol10 mg q6 h IV followed 100 mg q24 h orallyAloneN/AN/A5.1

Garg et al. [26]Case report26SeverePropranolol10 mg q12 h to 10 mg q8 h IVAloneN/AN/AN/A

Monteiro et al. [27]Case report27SeverePropranolol10 mg q8 hAloneN/AN/AN/A

Zheng et al. [9]Narrative review30Moderate, severePropranolol, labetalol, metoprolol20–60 mg q4-6 hr orallyIn combinationα2-Agonists, gabapentin, baclofen, bromocriptine, and long-acting benzodiazepinesN/AN/A

Ammar and Hussein [11]Randomized, double-blinded, placebo-controlled trial55ModeratePropranolol1 mg q6 hr IVAloneN/AN/AN/A